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Rethinking governance for trade and health
The mechanism for dispute settlement in preferential trade agreements risks riding roughshod over
health
Helen Walls research fellow, Richard Smith professor
London School of Hygiene and Tropical Medicine and Leverhulme Centre for Integrative Research on Agriculture and Health, London, UK
Strengthening governance for more “healthy” trade is a
recognised public health priority,1 and increasingly so given
recent shifts in the international trade regime.2 After the second
world war increasing trade liberalisation became a focus of
international attention, and the General Agreement on Tariffs
and Trade (GATT) was set up to coordinate international trade
agreements. This was highly successful, and average world tariff
rates fell from about 40% in 1948 to 4% in the early 1990s.3
At this time, GATT was replaced by the World Trade
Organization (WTO), which had an increased scope. However,
over the past two decades bilateral and regional trade agreements
have proliferated. These have generally been negotiated in
extreme secrecy, with increasingly “deep” commitments that
go beyond those required by the WTO.2 4 These commitments,
the specifics of which have been well documented,2 5-7 have
important implications for public health. One focus of concern
is the investor-state dispute settlement (ISDS)mechanism, which
allows foreign companies to sue host governments for
compensation when policy changes threaten their ability to
generate earnings from investments.8 Claims in investor-state
disputes are adjudicated in private tribunals (unlike regular
lawsuits in open court and themore transparent review processes
for within state disputes under theWTO system) with no appeals
process and without the consistency and learning from a system
of precedents.5 9-11
This dispute settlement mechanism is proposed in two key
preferential trade agreements currently under negotiation, the
Trans Pacific Partnership (TPP), which involves 12 Asia-Pacific
Rim countries,2 12 and the Transatlantic Trade and Investment
Partnership (TTIP), between the European Union and United
States.5 13 A salutary example of the public health implications
of investor-state dispute settlements is the litigation in response
to Australia’s introduction of legislation for plain packaged
cigarettes.10 14 But the deep commitments have far ranging
implications, including those relating to intellectual property,
with potential for “evergreening” drug patents—that is,
extending patents for slight changes to formulation without
demonstration of superior benefit.2 15
Such provisions in modern preferential trade agreements shift
the balance of policy making in favour of corporate interests,
limiting policy options available to governments to protect
public health, and making governments reluctant to legislate
for public services because they fear lawsuits from foreign
investors.2 5 16 This clearly challenges global, regional, and
national governance structures concerned with health and
healthcare.
To secure healthy trade, decision making processes need to
include health as well as economic objectives, tackling trade in
goods and services with direct negative effects on health.
However, to date, much of the discussion and research regarding
how to achieve such governance and what it would look like
has been limited to the global level. For example, it has focused
on institutions such as theWTO andWorld Health Organization.
Governance of trade and health at global level is important, but
the stalling of the WTO Doha Development Round and the
proliferation of bilateral and regional preferential trade
agreements with arguably greater public health risks emphasise
the critical nature of governance at regional and national
levels.2 17 Securing governance for healthy trade at these levels
poses particular challenges. Some of them result from the
different worldviews and large power imbalances between trade
and health sectors, including the secrecy surrounding the
negotiations and the vested corporate interests and well funded
lobbies influencing countries’ positions in the negotiations.11 18
Furthermore, developing the requisite regulatory capacities for
the negotiation, implementation, and ongoing management of
preferential trade agreements is expensive and skill intensive
and requires considerable infrastructure. Poorer countries will
especially struggle with this.17
Success requires the establishment of governance structures and
mechanisms that bridge current sectoral divides. These structures
and mechanisms must promote collaboration and build trust
between trade and health communities. There are some, albeit
limited, examples of this approach improving regional and
national regulatory capacity.17 19-22 In Brazil, for example,
responsibility for the examination and granting of
pharmaceutical patents has been split between the National
Sanitary Surveillance Agency and the Brazilian patent office,
giving more influence to a public health perspective.17 23 Given
scarce resources, it may be prudent for countries to focus on
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developing regulatory capacity in specific areas and then share
best practice within regions, perhaps working towards
developing regional regulatory mechanisms and structures.17
Specific goals may include stronger and more legally defensible
health exceptions or exemptions in preferential trade
agreements.11 17 For example, Faunce has suggested that
Australia should have negotiated health exemptions in
mechanisms for investor-state dispute settlement with regard
to plain packaging.10 Transparency in trade and investment
policy making should also be prioritised.24
The rise of bilateral and regional trade initiatives, and
concomitant reduction in influence of global institutions, makes
more focus and research on governance at regional and national
levels important, especially at the interface between these levels
and global institutions and structure. Much of the existing
research is not empirical and does not fully cover the
characteristics of the issue and political environment. Public
health researchers, practitioners, and policy makers must work
together to understand and develop the necessary structures and
mechanisms for governance at these levels. Without this, work
on strengthening governance for healthy trade may be made
less effective, or at worst irrelevant, by developments in bilateral
and regional agreements.
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